Gufivor-O Tablet contains Voriconazole 200 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of serious invasive fungal infections. Voriconazole exhibits potent activity against a wide range of fungal pathogens, including Aspergillus species, Candida species, and other rare molds and yeasts. It functions by inhibiting fungal cytochrome P450-dependent 14α-sterol demethylase, an essential enzyme in ergosterol biosynthesis, leading to disruption of fungal cell membrane integrity and growth inhibition. Gufivor-O is primarily prescribed for invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and infections caused by Scedosporium and Fusarium species. The tablet formulation allows for convenient oral administration with good bioavailability. Dosage should be individualized based on the severity of infection, patient weight, and hepatic function, with careful monitoring for potential adverse effects such as visual disturbances, hepatotoxicity, and skin reactions. Caution is advised when co-administered with drugs metabolized by the cytochrome P450 system due to potential drug interactions. Gufivor-O should be used under strict medical supervision, ensuring appropriate diagnostic confirmation of fungal infection and monitoring therapeutic response to optimize clinical outcomes.